The China needle-free drug delivery devices market is expected to grow at a CAGR of around 15.5% during the forecast period. High level of air pollution and significant number of smokers in China is boosting the demand for inhalers in the country. Additionally, rising geriatric population susceptible to asthma and COPD within the country is also driving the demand for inhalers. This is turn, drives the overall growth of the needle-free drug delivery devices industry. The increasing need for self-administration of drugs as in the case of diseases such as diabetes has enhanced the size of needle-free drug delivery devices industry in China. 

China needle-free drug delivery devices market is segmented on the basis of technology and application. Based on the technology, the market is segmented into inhaler technology, jet injectors, transdermal patch technology, others. Jet injectors are used for a broad range of applications due to their benefits such as rapid administration, faster response rates, and improved dosing accuracy. In addition, these devices offer better diffusion into tissues and are easily portable. Further, on the basis of application, the market is segmented into pain management, insulin delivery, vaccine delivery, pediatric injections, and others. 

Further, the report covers the analysis of several players operating in the market. Some of the key players operating in the market include 3M Co., Boerhinger Ingelheim International GmbH, GlaxoSmithKline PLC, Inovio Pharmaceuticals Inc., Ferring Holding SA, and others.

Research Methodology

The market study of the China needle-free drug delivery devices market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Authenticate databases such as the American Heart Association, the National Institute of Health, and the International Diabetes Federation.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report is intended for pharmaceutical and biotechnology companies, healthcare organizations, research institutes and academic institutes, investing companies and venture capitalists, hospitals and clinics, government organizations and regulatory agencies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, different products, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation

1. China Needle-Free Drug Delivery Devices Market Research and Analysis by Technology
2. China Needle-Free Drug Delivery Devices Market Research and Analysis by Application